Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 09, 2022 16:02 ET | Source: Revolution Medicines, Inc.

Revolution Medicines Reports Second Quarter 2022 Financial Results and Update on Corporate Progress

First two RAS(ON) Inhibitor drug candidates advance into clinical development Successful equity financing supports development of portfolio of targeted drug candidates for RAS-addicted cancers ...
July 28, 2022 16:02 ET | Source: Revolution Medicines, Inc.

Revolution Medicines to Report Financial Results for Second Quarter 2022 After Market Close on August 9, 2022

REDWOOD CITY, Calif., July 28, 2022 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers,...
July 22, 2022 16:02 ET | Source: Revolution Medicines, Inc.

Revolution Medicines Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

REDWOOD CITY, Calif., July 22, 2022 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today...
July 19, 2022 22:41 ET | Source: Revolution Medicines, Inc.

Revolution Medicines Announces Pricing of Upsized $230.0 Million Public Offering of Common Stock

REDWOOD CITY, Calif., July 19, 2022 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today...
July 19, 2022 16:01 ET | Source: Revolution Medicines, Inc.

Revolution Medicines Announces Commencement of Public Offering of Common Stock

REDWOOD CITY, Calif., July 19, 2022 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today...
July 13, 2022 07:00 ET | Source: Revolution Medicines, Inc.

Revolution Medicines Appoints Lorence Kim, M.D., Accomplished Health Care Industry Leader, to Board of Directors

REDWOOD CITY, Calif., July 13, 2022 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today...
June 28, 2022 07:00 ET | Source: Revolution Medicines, Inc.

Revolution Medicines Advances First RAS(ON) Inhibitor into Clinic, Dosing First Patient in Phase 1/1b Trial of RMC-6236

First-in-class, oral, RAS(ON) Inhibitor being evaluated initially in patients with cancers driven by KRASG12 mutations Sushil Patel, Ph.D., industry veteran with commercial oncology expertise,...
June 09, 2022 16:02 ET | Source: Revolution Medicines, Inc.

Revolution Medicines to Participate in the 43rd Annual Goldman Sachs Global Healthcare Conference

REDWOOD CITY, Calif., June 09, 2022 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today...
May 09, 2022 16:02 ET | Source: Revolution Medicines, Inc.

Revolution Medicines Reports First Quarter 2022 Financial Results and Update on Corporate Progress

Lead RAS(ON) Inhibitor drug candidates RMC-6236 (RASMULTI) and RMC-6291 (KRASG12C) approaching the clinic RMC-4630-03 Phase 2 trial evaluating RAS Companion Inhibitor RMC-4630 (SHP2) in combination...
April 21, 2022 16:05 ET | Source: Revolution Medicines, Inc.

Revolution Medicines to Report Financial Results for First Quarter 2022 After Market Close on May 9, 2022

REDWOOD CITY, Calif., April 21, 2022 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers,...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right